Breast Cancer Now media statements
We respond to findings from a Swedish trial about AI supported breast screening
In response to interim findings from a Swedish randomised control trial about AI-supported breast screening published in Lancet Oncology, Dr...
Breast Cancer Now responds to the decision by NICE to provisionally reject talazoparib (Talzenna)
Baroness Delyth Morgan, chief executive of Breast Cancer Now, said:
Breast Cancer Now respond to latest NHS Workforce Plan
Responding to the publication of the NHS long-term workforce plan, Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
Breast Cancer Now responds to news of Sarah, the Duchess of York's breast cancer diagnosis
In response to the news of Sarah, Duchess of York’s breast cancer diagnosis, Addie Mitchell, clinical nurse specialist at Breast Cancer Now,...
We respond to the publication of a new 10-year Cancer Strategy in Scotland
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
New research reveals most women diagnosed with early-stage breast cancer can expect to become “long-term survivors”
Baroness Delyth Morgan, chief executive at Breast Cancer Now said:
We welcome the SMC's approval of pembrolizumab for use on the NHS in Scotland
Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
Breast Cancer Now responds to Royal College of Radiologists (RCR) reports demonstrating scale of workforce shortages across the country and impacts on cancer patients
Baroness Delyth Morgan, chief executive of Breast Cancer Now, said:
We respond to new research which shows the drug ribociclib reduces the risk of breast cancer recurrence for some women
In response to interim findings from the NATALEE trial presented at ASCO on Friday 2nd June, 2023, Dr Kotryna Temcinaite, head of research c...
We welcome the SMC's approval of trastuzumab deruxtecan for use on the NHS in Scotland
Responding to the Scottish Medicines Consortium’s (SMC) decision to approve trastuzumab deruxtecan (Enhertu) for use on the NHS in Scotland,...
Breast Cancer Now respond to NICE’s decision to approve olaparib for use on the NHS.
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now said:
Breast Cancer Now responds to research about breast cancer risk and hormonal contraceptives
In response to research published in PLOS Medicine looking at breast cancer risk and combined and progestogen-only contraceptives, Dr Kotryn...